Can Emcure’s Cut-Price Eribulin Dull Halaven In India?

Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.

Ribbons
EMCURE HAS INTRODUCED A GENERIC VERSION OF HALAVEN AT A SHARPLY LOWER PRICE • Source: Shutterstock

Emcure Pharmaceuticals Ltd. appears to have thrown down the gauntlet to Eisai Co. Ltd. with the launch on the Indian market of its “cost-effective” generic version of the Japanese firm’s Halaven (eribulin) for the treatment of metastatic breast cancer (MBC).

Emcure’s eribulin (marketed as Eribilin), which the Indian firm claims is the world’s first generic version of Halaven, is priced at INR19,500 ($283

More from India

More from Focus On Asia